A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype

Table 1 Correlation between clinical parameters and early or late recurrence in 743 dataset

Clinical parameter		N	Early recurrence			Late recurrence
Clinical parameter		N	Pvalue	HR (95% CI)	N (event)	Pvalue	HR (95% CI)	N (event)
HER2	pos. vs. neg.	743	0.1378	1.36 (0.91 - 2.04)	207	0.7788	1.10 (0.57 - 2.13)	80
ER	pos. vs. neg.	743	0.0048	0.63 (0.46 - 0.87)	207	0.5023	1.19 (0.72 - 1.97)	80
PR	pos. vs. neg.	743	0.0004	0.61 (0.46 - 0.80)	207	0.1027	1.45 (0.93 - 2.28)	80
TNBC	TN vs. others	743	0.0031	1.77 (1.21 - 2.59)	207	0.0974	0.61 (0.34 - 1.10)	80
Tumor size	≥2 cm vs. <2 cm	456	0.0008	1.91 (1.31 - 2.78)	114	0.3184	1.29 (0.78 - 2.12)	67
Grade	Grade 3 vs. others	438	0.0038	1.87 (1.22 - 2.84)	110	0.0692	0.60 (0.35 - 1.04)	61
Age	≥50 vs. <50	457	0.9933	1.00 (0.69 - 1.44)	114	0.1144	0.67 (0.41 - 1.10)	66

CI: confidence interval; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; HR, hazard ratio; PR: progesterone receptor; TNBC: triple-negative breast cancer.